BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 25475539)

  • 1. Bacillus Calmette-Guérin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system.
    Clothier HJ; Hosking L; Crawford NW; Russell M; Easton ML; Quinn JA; Buttery JP
    Drug Saf; 2015 Jan; 38(1):79-86. PubMed ID: 25475539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following immunisation with bacille Calmette-Guérin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine.
    Hendry AJ; Dey A; Beard FH; Khandaker G; Hill R; Macartney KK
    Commun Dis Intell Q Rep; 2016 Dec; 40(4):E470-E474. PubMed ID: 28043221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of bacille Calmette-Guérin immunisation programs in Australia.
    Khandaker G; Beard FH; Dey A; Coulter C; Hendry AJ; Macartney KK
    Commun Dis Intell Q Rep; 2017 Mar; 41(1):E33-E48. PubMed ID: 28385137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018.
    Clothier HJ; Lawrie J; Lewis G; Russell M; Crawford NW; Buttery JP
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32536336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual report: surveillance of adverse events following immunisation in Australia, 2008.
    Menzies R; Mahajan D; Gold MS; Roomiani I; McIntyre P; Lawrence G
    Commun Dis Intell Q Rep; 2009 Dec; 33(4):365-81. PubMed ID: 20301966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
    Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
    Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria.
    Clothier HJ; Crawford NW; Kempe A; Buttery JP
    Commun Dis Intell Q Rep; 2011 Dec; 35(4):294-8. PubMed ID: 22624490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual report: surveillance of adverse events following immunisation in Australia, 2007.
    Lawrence G; Gold MS; Hill R; Deeks S; Glasswell A; McIntyre PB
    Commun Dis Intell Q Rep; 2008 Dec; 32(4):371-87. PubMed ID: 19374268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia.
    Baxter CM; Clothier HJ; Perrett KP
    Hum Vaccin Immunother; 2018; 14(8):2088-2092. PubMed ID: 29624467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of adherence to pre-vaccination precautions and AEFI reporting practices during BCG vaccination in 4 hospitals in Ghana.
    Yamoah P; Mensah KB; Padayachee N; Bangalee V; Oosthuizen F
    Hum Vaccin Immunother; 2023 Dec; 19(1):2199654. PubMed ID: 37127290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
    Guo B; Page A; Wang H; Taylor R; McIntyre P
    Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010].
    Zhang LP; Yu F; Jin BF; Wang Y; Xu HL; DU Y
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):859-64. PubMed ID: 23302620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.